Full-year profit views are for The J.M. Smucker Company to earn $7.7 in current year and drop profits by almost 28.33% over last year's earnings of $6. These analysts have also projected a Low Estimate of $1.92/share and a High Estimate of $2.06/share.

Comparable net sales for fiscal year 2017 is expected to be down 3 percent. Seven analysts surveyed by Zacks expected $1.92 billion.

In case of Revenue Estimates, 12 analysts have provided their consensus Average Revenue Estimates for The J.M. Smucker Company as 1.92 Billion. Analysts' estimates typically exclude special items. The stock has moved up across its 50-day moving average of $133.93.

Many brokerage firms are involved in issuing their ratings on The J.M. Smucker Company (NYSE:SJM). The company reported $2.05 EPS for the quarter, beating the analyst consensus estimate by $ 0.12.

J.M. Smucker Company (The) is expected* to report earnings on 02/17/2017 before market open. On 15-Feb-17 Deutsche Bank Initiated The J.M. Smucker Company Stock to Hold. Full-year sales forecasts are pegged at $7.48B, representing a drop of almost -4.23% over last fiscal year's revenues of $7.81B. As the past trend shows, The J.M. Smucker Company's stock price has plunged after earnings in 16 of the last 27 quarters.

On the sales side, SJM's revenues are expected to retreat to $1.97B versus prior year's Q3 result of $1.97B. Shares of The J.M. Smucker Company rose by 0.1% in the last five trading days and 4.2% for the last 4 weeks.

The Stock now has Analyst' mean Recommendation of 2.7 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

Ocular Therapeutix, Inc.is estimated to report earnings on 03/09/2017.

The company's net income fell to $134.6 million, or $1.16 per share, in the third quarter ended January 31 from $185.3 million, or $1.55 per share, a year earlier. It closed the session at $124.85 with a volume of 1954400 shares. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.47. Year-to-Date the stock performance stands at 8.22%. The Return on Equity (ROE) value stands at 10.1%.